Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44

Chinese Medical Journal

Volumn 121, Issue 17, 2008, Pages 1702-1706

  Liu, Fang Jun ^a   Gui, Song Bai ^b   Li, Chu Zhong ^a   Sun, Ze Lin ^a   Zhang, Ya Zhuo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Glioblastoma; Iressa

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; F 90; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MEGADOSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EID: 52949119487     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200809010-00022     Document Type: Article

References (20)

1. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11.
2. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8: 3250-3258.
3. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002; 98: 463-469.
4. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002; 62: 5242-5247.
5. Xie D, Zeng YX, Wang HJ, Tai LS, Wen JM, Tao Y, et al. Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol (Berl) 2005; 110: 481-489.
6. Jarvela S, Helin H, Haapasalo J, Jarvela T, Junttila TT, Elenius K, et al. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol 2006; 32: 441-450.
7. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004; 30: 1-17.
8. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11.
9. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 2005; 74: 77-86.
10. Jin W, Xu X, Yang T, Hua Z. p53 mutation, EG-FR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. Chin Med J 2000; 113: 662-666.
11. Liu KJ, Chen CT, Hu WS, Hung YM, Hsu CY, Chuang BF, et al. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme. Int J Oncol 2004; 24: 581-590.
12. Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006; 13 Suppl 1: S45-51.
13. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51: 410-418.
14. Lewis TS, Shapiro PS, Ahn NG, Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
15. Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 2003; 23: 641-648.
16. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998; 153: 1411-1423.
17. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-822.
18. Wu SJ, Ng LT. MAPK inhibitors and pifithrin-alpha block cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells. Food Chem Toxicol 2007; 45: 2446-2453.
19. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13: 491-498.
20. 125I in rats. Chin J Minim Invasive Neurosurg (Chin) 2006; 11: 171-174.